Which has higher valuation & earnings, DSGN or TLX?

Telix Pharmaceuticals has higher revenue and earnings than Design Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Design Therapeutics N/A N/A -$69.79M -$1.18 N/A Telix Pharmaceuticals $803.79M 5.10 -$7.12M N/A N/A

Is DSGN or TLX more profitable?

Telix Pharmaceuticals' return on equity of 0.00% beat Design Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Design Therapeutics N/A -34.03% -32.05% Telix Pharmaceuticals N/A N/A N/A

Does the media favor DSGN or TLX?

In the previous week, Telix Pharmaceuticals had 8 more articles in the media than Design Therapeutics. MarketBeat recorded 12 mentions for Telix Pharmaceuticals and 4 mentions for Design Therapeutics. Design Therapeutics' average media sentiment score of 0.88 beat Telix Pharmaceuticals' score of 0.18 indicating that Design Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Design Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Telix Pharmaceuticals 1 Very Positive mention(s) 5 Positive mention(s) 2 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral

Is DSGN or AMLX more profitable?

Design Therapeutics' return on equity of -34.03% beat Amylyx Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Design Therapeutics N/A -34.03% -32.05% Amylyx Pharmaceuticals N/A -52.92% -48.53%

Does the media refer more to DSGN or AMLX?

In the previous week, Amylyx Pharmaceuticals had 2 more articles in the media than Design Therapeutics. MarketBeat recorded 6 mentions for Amylyx Pharmaceuticals and 4 mentions for Design Therapeutics. Amylyx Pharmaceuticals' average media sentiment score of 1.42 beat Design Therapeutics' score of 0.88 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Design Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amylyx Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to DSGN or RCUS?

In the previous week, Arcus Biosciences had 1 more articles in the media than Design Therapeutics. MarketBeat recorded 5 mentions for Arcus Biosciences and 4 mentions for Design Therapeutics. Arcus Biosciences' average media sentiment score of 1.53 beat Design Therapeutics' score of 0.88 indicating that Arcus Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Design Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arcus Biosciences 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer IOVA or DSGN?

In the previous week, Iovance Biotherapeutics had 4 more articles in the media than Design Therapeutics. MarketBeat recorded 8 mentions for Iovance Biotherapeutics and 4 mentions for Design Therapeutics. Iovance Biotherapeutics' average media sentiment score of 1.15 beat Design Therapeutics' score of 0.88 indicating that Iovance Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Iovance Biotherapeutics 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Design Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to DSGN or GRAL?

In the previous week, GRAIL had 4 more articles in the media than Design Therapeutics. MarketBeat recorded 8 mentions for GRAIL and 4 mentions for Design Therapeutics. GRAIL's average media sentiment score of 0.90 beat Design Therapeutics' score of 0.88 indicating that GRAIL is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Design Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GRAIL 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Design Therapeutics (DSGN) Competitors

$15.09 -0.05 (-0.33%)

As of 02:32 PM Eastern

Compare

DSGN vs. TLX, AMLX, RCUS, IOVA, and GRAL

Should you buy Design Therapeutics stock or one of its competitors? Design Therapeutics's main competitors and comparable companies include Telix Pharmaceuticals (TLX), Amylyx Pharmaceuticals (AMLX), Arcus Biosciences (RCUS), Iovance Biotherapeutics (IOVA), and GRAIL (GRAL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Design Therapeutics compare to Telix Pharmaceuticals?

Design Therapeutics (NASDAQ:DSGN) and Telix Pharmaceuticals (NASDAQ:TLX) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, risk, profitability, institutional ownership, media sentiment, earnings and dividends.

56.6% of Design Therapeutics shares are owned by institutional investors. 17.1% of Design Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Telix Pharmaceuticals had 8 more articles in the media than Design Therapeutics. MarketBeat recorded 12 mentions for Telix Pharmaceuticals and 4 mentions for Design Therapeutics. Design Therapeutics' average media sentiment score of 0.88 beat Telix Pharmaceuticals' score of 0.18 indicating that Design Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Design Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Telix Pharmaceuticals	1 Very Positive mention(s)	5 Positive mention(s)	2 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Telix Pharmaceuticals' return on equity of 0.00% beat Design Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Design Therapeutics	N/A	-34.03%	-32.05%
Telix Pharmaceuticals	N/A	N/A	N/A

Telix Pharmaceuticals has higher revenue and earnings than Design Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Design Therapeutics	N/A	N/A	-$69.79M	-$1.18	N/A
Telix Pharmaceuticals	$803.79M	5.10	-$7.12M	N/A	N/A

Design Therapeutics has a beta of 1.66, indicating that its share price is 66% more volatile than the broader market. Comparatively, Telix Pharmaceuticals has a beta of -0.17, indicating that its share price is 117% less volatile than the broader market.

Design Therapeutics currently has a consensus price target of $16.50, suggesting a potential upside of 8.65%. Telix Pharmaceuticals has a consensus price target of $20.40, suggesting a potential upside of 69.03%. Given Telix Pharmaceuticals' higher possible upside, analysts clearly believe Telix Pharmaceuticals is more favorable than Design Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Telix Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.86

Summary

Design Therapeutics and Telix Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks.

How does Design Therapeutics compare to Amylyx Pharmaceuticals?

Design Therapeutics (NASDAQ:DSGN) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, media sentiment, valuation and earnings.

56.6% of Design Therapeutics shares are owned by institutional investors. Comparatively, 95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. 17.1% of Design Therapeutics shares are owned by company insiders. Comparatively, 10.9% of Amylyx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Design Therapeutics has a beta of 1.66, indicating that its stock price is 66% more volatile than the broader market. Comparatively, Amylyx Pharmaceuticals has a beta of -0.13, indicating that its stock price is 113% less volatile than the broader market.

Design Therapeutics' return on equity of -34.03% beat Amylyx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Design Therapeutics	N/A	-34.03%	-32.05%
Amylyx Pharmaceuticals	N/A	-52.92%	-48.53%

Design Therapeutics has higher earnings, but lower revenue than Amylyx Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Design Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Design Therapeutics	N/A	N/A	-$69.79M	-$1.18	N/A
Amylyx Pharmaceuticals	$87.37M	43.30	-$144.74M	-$1.43	N/A

Design Therapeutics presently has a consensus price target of $16.50, suggesting a potential upside of 8.65%. Amylyx Pharmaceuticals has a consensus price target of $36.50, suggesting a potential upside of 7.51%. Given Design Therapeutics' higher probable upside, research analysts clearly believe Design Therapeutics is more favorable than Amylyx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Amylyx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Amylyx Pharmaceuticals had 2 more articles in the media than Design Therapeutics. MarketBeat recorded 6 mentions for Amylyx Pharmaceuticals and 4 mentions for Design Therapeutics. Amylyx Pharmaceuticals' average media sentiment score of 1.42 beat Design Therapeutics' score of 0.88 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Design Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amylyx Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Design Therapeutics beats Amylyx Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Design Therapeutics compare to Arcus Biosciences?

Design Therapeutics (NASDAQ:DSGN) and Arcus Biosciences (NYSE:RCUS) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, analyst recommendations, valuation and dividends.

Design Therapeutics has higher earnings, but lower revenue than Arcus Biosciences. Design Therapeutics is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Design Therapeutics	N/A	N/A	-$69.79M	-$1.18	N/A
Arcus Biosciences	$247M	15.13	-$353M	-$3.90	N/A

Design Therapeutics has a net margin of 0.00% compared to Arcus Biosciences' net margin of -393.16%. Design Therapeutics' return on equity of -34.03% beat Arcus Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Design Therapeutics	N/A	-34.03%	-32.05%
Arcus Biosciences	-393.16%	-89.54%	-45.61%

Design Therapeutics currently has a consensus target price of $16.50, indicating a potential upside of 8.65%. Arcus Biosciences has a consensus target price of $38.30, indicating a potential upside of 30.48%. Given Arcus Biosciences' higher probable upside, analysts clearly believe Arcus Biosciences is more favorable than Design Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58

Design Therapeutics has a beta of 1.66, meaning that its share price is 66% more volatile than the broader market. Comparatively, Arcus Biosciences has a beta of 0.81, meaning that its share price is 19% less volatile than the broader market.

In the previous week, Arcus Biosciences had 1 more articles in the media than Design Therapeutics. MarketBeat recorded 5 mentions for Arcus Biosciences and 4 mentions for Design Therapeutics. Arcus Biosciences' average media sentiment score of 1.53 beat Design Therapeutics' score of 0.88 indicating that Arcus Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Design Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arcus Biosciences	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

56.6% of Design Therapeutics shares are held by institutional investors. Comparatively, 92.9% of Arcus Biosciences shares are held by institutional investors. 17.1% of Design Therapeutics shares are held by insiders. Comparatively, 7.6% of Arcus Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Design Therapeutics beats Arcus Biosciences on 9 of the 16 factors compared between the two stocks.

How does Design Therapeutics compare to Iovance Biotherapeutics?

Iovance Biotherapeutics (NASDAQ:IOVA) and Design Therapeutics (NASDAQ:DSGN) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, risk and dividends.

Iovance Biotherapeutics presently has a consensus price target of $8.89, suggesting a potential upside of 1.18%. Design Therapeutics has a consensus price target of $16.50, suggesting a potential upside of 8.65%. Given Design Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Design Therapeutics is more favorable than Iovance Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iovance Biotherapeutics	2 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.45
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Design Therapeutics has lower revenue, but higher earnings than Iovance Biotherapeutics. Design Therapeutics is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iovance Biotherapeutics	$324.97M	12.25	-$390.98M	-$0.73	N/A
Design Therapeutics	N/A	N/A	-$69.79M	-$1.18	N/A

Design Therapeutics has a net margin of 0.00% compared to Iovance Biotherapeutics' net margin of -89.11%. Design Therapeutics' return on equity of -34.03% beat Iovance Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Iovance Biotherapeutics	-89.11%	-40.51%	-31.65%
Design Therapeutics	N/A	-34.03%	-32.05%

Iovance Biotherapeutics has a beta of 0.83, suggesting that its share price is 17% less volatile than the broader market. Comparatively, Design Therapeutics has a beta of 1.66, suggesting that its share price is 66% more volatile than the broader market.

77.0% of Iovance Biotherapeutics shares are held by institutional investors. Comparatively, 56.6% of Design Therapeutics shares are held by institutional investors. 7.8% of Iovance Biotherapeutics shares are held by insiders. Comparatively, 17.1% of Design Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Iovance Biotherapeutics had 4 more articles in the media than Design Therapeutics. MarketBeat recorded 8 mentions for Iovance Biotherapeutics and 4 mentions for Design Therapeutics. Iovance Biotherapeutics' average media sentiment score of 1.15 beat Design Therapeutics' score of 0.88 indicating that Iovance Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Iovance Biotherapeutics	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Design Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Iovance Biotherapeutics and Design Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Design Therapeutics compare to GRAIL?

Design Therapeutics (NASDAQ:DSGN) and GRAIL (NASDAQ:GRAL) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, media sentiment, institutional ownership, analyst recommendations, dividends and risk.

Design Therapeutics presently has a consensus price target of $16.50, indicating a potential upside of 8.65%. GRAIL has a consensus price target of $67.78, indicating a potential downside of 15.20%. Given Design Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Design Therapeutics is more favorable than GRAIL.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
GRAIL	1 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.30

Design Therapeutics has a net margin of 0.00% compared to GRAIL's net margin of -236.95%. GRAIL's return on equity of -15.88% beat Design Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Design Therapeutics	N/A	-34.03%	-32.05%
GRAIL	-236.95%	-15.88%	-14.02%

In the previous week, GRAIL had 4 more articles in the media than Design Therapeutics. MarketBeat recorded 8 mentions for GRAIL and 4 mentions for Design Therapeutics. GRAIL's average media sentiment score of 0.90 beat Design Therapeutics' score of 0.88 indicating that GRAIL is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Design Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GRAIL	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Design Therapeutics has a beta of 1.66, indicating that its share price is 66% more volatile than the broader market. Comparatively, GRAIL has a beta of 3.25, indicating that its share price is 225% more volatile than the broader market.

Design Therapeutics has higher earnings, but lower revenue than GRAIL. Design Therapeutics is trading at a lower price-to-earnings ratio than GRAIL, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Design Therapeutics	N/A	N/A	-$69.79M	-$1.18	N/A
GRAIL	$147.17M	24.26	-$408.35M	-$9.75	N/A

56.6% of Design Therapeutics shares are owned by institutional investors. 17.1% of Design Therapeutics shares are owned by company insiders. Comparatively, 1.8% of GRAIL shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Design Therapeutics beats GRAIL on 9 of the 16 factors compared between the two stocks.

Get Design Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DSGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DSGN vs. The Competition

Export

Metric	Design Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$950.34M	$3.91B	$7.06B	$12.89B
Dividend Yield	N/A	3.60%	2.54%	9.14%
P/E Ratio	-12.87	12.54	271.73	25.42
Price / Sales	N/A	1,354.85	621.93	93.08
Price / Cash	N/A	45.00	28.92	35.62
Price / Book	4.07	16.18	10.97	6.44
Net Income	-$69.79M	-$22.81M	$3.48B	$358.18M
7 Day Performance	0.30%	0.95%	0.29%	1.02%
1 Month Performance	8.55%	5.46%	3.33%	-0.48%
1 Year Performance	160.93%	48.53%	23.11%	13.82%

Design Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DSGN Design Therapeutics	1.1552 of 5 stars	$15.11 -0.2%	$16.50 +9.2%	+134.7%	$946.21M	N/A	N/A	40	Positive News
TLX Telix Pharmaceuticals	3.9518 of 5 stars	$10.85 -2.2%	$20.40 +88.0%	+31.8%	$3.77B	$803.79M	N/A	1,184
AMLX Amylyx Pharmaceuticals	2.4077 of 5 stars	$33.81 +0.2%	$36.50 +8.0%	+234.3%	$3.76B	$87.37M	N/A	200	Positive News
RCUS Arcus Biosciences	2.8834 of 5 stars	$29.59 +1.1%	$37.80 +27.7%	+142.8%	$3.73B	$247M	N/A	500	Positive News Analyst Forecast
IOVA Iovance Biotherapeutics	1.4527 of 5 stars	$8.28 +1.3%	$8.89 +7.4%	+253.0%	$3.70B	$263.50M	N/A	500	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DSGN) was last updated on 9/8/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Design Therapeutics (DSGN) Competitors

DSGN vs. TLX, AMLX, RCUS, IOVA, and GRAL

How does Design Therapeutics compare to Telix Pharmaceuticals?

Summary

How does Design Therapeutics compare to Amylyx Pharmaceuticals?

Summary

How does Design Therapeutics compare to Arcus Biosciences?

Summary

How does Design Therapeutics compare to Iovance Biotherapeutics?

Summary

How does Design Therapeutics compare to GRAIL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DSGN vs. The Competition

Design Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Design Therapeutics (DSGN) Competitors

DSGN vs. TLX, AMLX, RCUS, IOVA, and GRAL

How does Design Therapeutics compare to Telix Pharmaceuticals?

Do institutionals & insiders hold more shares of DSGN or TLX?

Does the media favor DSGN or TLX?

Is DSGN or TLX more profitable?

Which has higher valuation & earnings, DSGN or TLX?

Which has more volatility and risk, DSGN or TLX?

Do analysts rate DSGN or TLX?

Summary

How does Design Therapeutics compare to Amylyx Pharmaceuticals?

Do institutionals & insiders hold more shares of DSGN or AMLX?

Which has more risk and volatility, DSGN or AMLX?

Is DSGN or AMLX more profitable?

Which has stronger earnings & valuation, DSGN or AMLX?

Do analysts rate DSGN or AMLX?

Does the media refer more to DSGN or AMLX?

Summary

How does Design Therapeutics compare to Arcus Biosciences?

Which has stronger earnings & valuation, DSGN or RCUS?

Is DSGN or RCUS more profitable?

Do analysts prefer DSGN or RCUS?

Which has more risk and volatility, DSGN or RCUS?

Does the media refer more to DSGN or RCUS?

Do insiders and institutionals believe in DSGN or RCUS?

Summary

How does Design Therapeutics compare to Iovance Biotherapeutics?

Do analysts recommend IOVA or DSGN?

Which has preferable earnings and valuation, IOVA or DSGN?

Is IOVA or DSGN more profitable?

Which has more risk and volatility, IOVA or DSGN?

Do insiders & institutionals hold more shares of IOVA or DSGN?

Does the media prefer IOVA or DSGN?

Summary

How does Design Therapeutics compare to GRAIL?

Do analysts recommend DSGN or GRAL?

Is DSGN or GRAL more profitable?

Does the media refer more to DSGN or GRAL?

Which has more volatility & risk, DSGN or GRAL?

Which has preferable valuation & earnings, DSGN or GRAL?

Do institutionals & insiders believe in DSGN or GRAL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DSGN vs. The Competition

Design Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools